Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

Latest News

March 1, 2011

NanoART for Improved Drug Delivery


The delivery of antiretroviral nano-formulations (nanoART) to virus target cells and tissue sanctuaries could reduce toxicities and help overcome the limitations in pharmacokinetics and biodistribution seen with current antiretroviral formulations. A posters on the dispersion of ART to tissue and target cells in mice was presented by the University of Nebraska Medical Center at the 18th Conference on Retroviruses and Opportunistic Infections today, which evaluated nanoART using efavirenz, atazanavir and ritonavir.

NanoART was delivered to mice via injection on a weekly basis and concentrations of the ART was measured in liver, spleen, kidney, and lung tissue as well as the effect of NanoART on HIV-infected peripheral blood. Treatment with NanoART let to 100-fold reduction in viral antigen compared to control and 20-fold reduction compared to unformulated drug treatment. PK studies of clinically relevant nanoART were observed and bioavailability data showed retention of NanoART in all tissue up to 14 days following administration of drug.

These studies in mice demonstrated that NanoART is very bio-available to tissue sanctuaries of HIV in the lung, liver, spleen and kidney, have little toxicity and are efficacious in decreasing HIV viral load. Many future studies are planned to evaluate this potential simplification of drug regimens and may help to eliminate HIV from tissue reservoirs in humans.

Reference: Nowacek A, Kadiu I, Balkundi S, et al. NanoART for Improved Antiretroviral Drug Delivery. Presented February 28, 2011, at 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA. Poster Presentation 532.


Source: Reporting for PRN News from Boston, MA: A.C. Demidont, DO